Clinical Trial

Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To learn if olverembatinib can help to control newly diagnosed CML in the chronic phase.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-02-04; most recent amendment 2026-05-18.
Status change: Not Yet Recruiting → Recruiting 2025-10-13
Trial Details
NCT Number NCT06817720
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Ascentage Pharma Group Inc.
Conditions Chronic Myeloid Leukemia
Enrollment 50 participants
Start Date 2025-10-13
Primary Completion 2027-03-07 (estimated)
Study Completion 2027-03-07 (estimated)
Updated on ClinicalTrials.gov 2026-05-20